nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Fatigue—Sunitinib—pancreatic cancer	0.00138	0.0021	CcSEcCtD
Solifenacin—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00138	0.0021	CcSEcCtD
Solifenacin—Cough—Gemcitabine—pancreatic cancer	0.00137	0.00209	CcSEcCtD
Solifenacin—Constipation—Sunitinib—pancreatic cancer	0.00137	0.00209	CcSEcCtD
Solifenacin—Hypertension—Gemcitabine—pancreatic cancer	0.00136	0.00207	CcSEcCtD
Solifenacin—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.00135	0.00206	CcSEcCtD
Solifenacin—Asthenia—Tamoxifen—pancreatic cancer	0.00134	0.00204	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00133	0.00203	CcSEcCtD
Solifenacin—Confusional state—Irinotecan—pancreatic cancer	0.00133	0.00203	CcSEcCtD
Solifenacin—Asthenia—Erlotinib—pancreatic cancer	0.00133	0.00202	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Epirubicin—pancreatic cancer	0.00132	0.00202	CcSEcCtD
Solifenacin—Pruritus—Tamoxifen—pancreatic cancer	0.00132	0.00202	CcSEcCtD
Solifenacin—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00132	0.00201	CcSEcCtD
Solifenacin—Renal impairment—Epirubicin—pancreatic cancer	0.00131	0.002	CcSEcCtD
Solifenacin—Infection—Irinotecan—pancreatic cancer	0.00131	0.002	CcSEcCtD
Solifenacin—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00131	0.00199	CcSEcCtD
Solifenacin—Pruritus—Erlotinib—pancreatic cancer	0.00131	0.00199	CcSEcCtD
Solifenacin—Nervous system disorder—Irinotecan—pancreatic cancer	0.00129	0.00197	CcSEcCtD
Solifenacin—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00128	0.00196	CcSEcCtD
Solifenacin—Infection—Gemcitabine—pancreatic cancer	0.00127	0.00194	CcSEcCtD
Solifenacin—Confusional state—Fluorouracil—pancreatic cancer	0.00127	0.00194	CcSEcCtD
Solifenacin—Pharyngitis—Docetaxel—pancreatic cancer	0.00127	0.00194	CcSEcCtD
Solifenacin—Urinary tract disorder—Docetaxel—pancreatic cancer	0.00127	0.00193	CcSEcCtD
Solifenacin—Abdominal pain—Sunitinib—pancreatic cancer	0.00126	0.00193	CcSEcCtD
Solifenacin—Oedema peripheral—Docetaxel—pancreatic cancer	0.00126	0.00193	CcSEcCtD
Solifenacin—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00126	0.00192	CcSEcCtD
Solifenacin—Connective tissue disorder—Docetaxel—pancreatic cancer	0.00126	0.00192	CcSEcCtD
Solifenacin—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00126	0.00192	CcSEcCtD
Solifenacin—Urethral disorder—Docetaxel—pancreatic cancer	0.00126	0.00192	CcSEcCtD
Solifenacin—Infection—Fluorouracil—pancreatic cancer	0.00125	0.00191	CcSEcCtD
Solifenacin—Skin disorder—Gemcitabine—pancreatic cancer	0.00125	0.0019	CcSEcCtD
Solifenacin—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00124	0.00189	CcSEcCtD
Solifenacin—Dizziness—Tamoxifen—pancreatic cancer	0.00123	0.00188	CcSEcCtD
Solifenacin—Tachycardia—Fluorouracil—pancreatic cancer	0.00123	0.00188	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Doxorubicin—pancreatic cancer	0.00123	0.00187	CcSEcCtD
Solifenacin—Dizziness—Erlotinib—pancreatic cancer	0.00122	0.00186	CcSEcCtD
Solifenacin—Renal impairment—Doxorubicin—pancreatic cancer	0.00122	0.00185	CcSEcCtD
Solifenacin—Erythema multiforme—Docetaxel—pancreatic cancer	0.00121	0.00185	CcSEcCtD
Solifenacin—Eye disorder—Docetaxel—pancreatic cancer	0.0012	0.00183	CcSEcCtD
Solifenacin—Cardiac disorder—Docetaxel—pancreatic cancer	0.00119	0.00181	CcSEcCtD
Solifenacin—Vomiting—Tamoxifen—pancreatic cancer	0.00119	0.00181	CcSEcCtD
Solifenacin—Hypersensitivity—Sunitinib—pancreatic cancer	0.00118	0.0018	CcSEcCtD
Solifenacin—Rash—Tamoxifen—pancreatic cancer	0.00118	0.0018	CcSEcCtD
Solifenacin—Dermatitis—Tamoxifen—pancreatic cancer	0.00118	0.00179	CcSEcCtD
Solifenacin—Vomiting—Erlotinib—pancreatic cancer	0.00117	0.00179	CcSEcCtD
Solifenacin—Somnolence—Irinotecan—pancreatic cancer	0.00117	0.00179	CcSEcCtD
Solifenacin—Headache—Tamoxifen—pancreatic cancer	0.00117	0.00178	CcSEcCtD
Solifenacin—Rash—Erlotinib—pancreatic cancer	0.00116	0.00178	CcSEcCtD
Solifenacin—Dermatitis—Erlotinib—pancreatic cancer	0.00116	0.00178	CcSEcCtD
Solifenacin—Angiopathy—Docetaxel—pancreatic cancer	0.00116	0.00177	CcSEcCtD
Solifenacin—Dyspepsia—Irinotecan—pancreatic cancer	0.00116	0.00177	CcSEcCtD
Solifenacin—Immune system disorder—Docetaxel—pancreatic cancer	0.00116	0.00177	CcSEcCtD
Solifenacin—Headache—Erlotinib—pancreatic cancer	0.00116	0.00177	CcSEcCtD
Solifenacin—Mediastinal disorder—Docetaxel—pancreatic cancer	0.00116	0.00176	CcSEcCtD
Solifenacin—Liver function test abnormal—Epirubicin—pancreatic cancer	0.00115	0.00176	CcSEcCtD
Solifenacin—Asthenia—Sunitinib—pancreatic cancer	0.00115	0.00175	CcSEcCtD
Solifenacin—Dry skin—Epirubicin—pancreatic cancer	0.00115	0.00175	CcSEcCtD
Solifenacin—Decreased appetite—Irinotecan—pancreatic cancer	0.00115	0.00175	CcSEcCtD
Solifenacin—Abdominal pain upper—Epirubicin—pancreatic cancer	0.00114	0.00174	CcSEcCtD
Solifenacin—Somnolence—Gemcitabine—pancreatic cancer	0.00114	0.00174	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00114	0.00173	CcSEcCtD
Solifenacin—Fatigue—Irinotecan—pancreatic cancer	0.00114	0.00173	CcSEcCtD
Solifenacin—Pruritus—Sunitinib—pancreatic cancer	0.00113	0.00173	CcSEcCtD
Solifenacin—Constipation—Irinotecan—pancreatic cancer	0.00113	0.00172	CcSEcCtD
Solifenacin—Mental disorder—Docetaxel—pancreatic cancer	0.00112	0.00171	CcSEcCtD
Solifenacin—Somnolence—Fluorouracil—pancreatic cancer	0.00112	0.00171	CcSEcCtD
Solifenacin—Malnutrition—Docetaxel—pancreatic cancer	0.00112	0.0017	CcSEcCtD
Solifenacin—Decreased appetite—Gemcitabine—pancreatic cancer	0.00112	0.0017	CcSEcCtD
Solifenacin—Dyspepsia—Fluorouracil—pancreatic cancer	0.00111	0.00169	CcSEcCtD
Solifenacin—Nausea—Tamoxifen—pancreatic cancer	0.00111	0.00169	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00111	0.00169	CcSEcCtD
Solifenacin—Fatigue—Gemcitabine—pancreatic cancer	0.00111	0.00169	CcSEcCtD
Solifenacin—Muscular weakness—Epirubicin—pancreatic cancer	0.0011	0.00168	CcSEcCtD
Solifenacin—Constipation—Gemcitabine—pancreatic cancer	0.0011	0.00167	CcSEcCtD
Solifenacin—Nausea—Erlotinib—pancreatic cancer	0.0011	0.00167	CcSEcCtD
Solifenacin—Decreased appetite—Fluorouracil—pancreatic cancer	0.0011	0.00167	CcSEcCtD
Solifenacin—Dysgeusia—Docetaxel—pancreatic cancer	0.00109	0.00167	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00109	0.00166	CcSEcCtD
Solifenacin—Feeling abnormal—Irinotecan—pancreatic cancer	0.00109	0.00166	CcSEcCtD
Solifenacin—Influenza—Epirubicin—pancreatic cancer	0.00108	0.00165	CcSEcCtD
Solifenacin—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00108	0.00164	CcSEcCtD
Solifenacin—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.00107	0.00163	CcSEcCtD
Solifenacin—Dry skin—Doxorubicin—pancreatic cancer	0.00106	0.00162	CcSEcCtD
Solifenacin—Dizziness—Sunitinib—pancreatic cancer	0.00106	0.00161	CcSEcCtD
Solifenacin—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00106	0.00161	CcSEcCtD
Solifenacin—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.00106	0.00161	CcSEcCtD
Solifenacin—Abdominal pain—Irinotecan—pancreatic cancer	0.00104	0.00159	CcSEcCtD
Solifenacin—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00104	0.00159	CcSEcCtD
Solifenacin—Muscular weakness—Doxorubicin—pancreatic cancer	0.00102	0.00156	CcSEcCtD
Solifenacin—Vomiting—Sunitinib—pancreatic cancer	0.00102	0.00155	CcSEcCtD
Solifenacin—Dysuria—Epirubicin—pancreatic cancer	0.00101	0.00154	CcSEcCtD
Solifenacin—Rash—Sunitinib—pancreatic cancer	0.00101	0.00154	CcSEcCtD
Solifenacin—Dermatitis—Sunitinib—pancreatic cancer	0.00101	0.00154	CcSEcCtD
Solifenacin—Urticaria—Fluorouracil—pancreatic cancer	0.001	0.00153	CcSEcCtD
Solifenacin—Headache—Sunitinib—pancreatic cancer	0.001	0.00153	CcSEcCtD
Solifenacin—Influenza—Doxorubicin—pancreatic cancer	0.000999	0.00152	CcSEcCtD
Solifenacin—Palpitations—Docetaxel—pancreatic cancer	0.000986	0.0015	CcSEcCtD
Solifenacin—Cough—Docetaxel—pancreatic cancer	0.000974	0.00149	CcSEcCtD
Solifenacin—Hypersensitivity—Irinotecan—pancreatic cancer	0.000971	0.00148	CcSEcCtD
Solifenacin—Hypertension—Docetaxel—pancreatic cancer	0.000963	0.00147	CcSEcCtD
Solifenacin—Infestation—Epirubicin—pancreatic cancer	0.000963	0.00147	CcSEcCtD
Solifenacin—Infestation NOS—Epirubicin—pancreatic cancer	0.000963	0.00147	CcSEcCtD
Solifenacin—Nausea—Sunitinib—pancreatic cancer	0.00095	0.00145	CcSEcCtD
Solifenacin—Renal failure—Epirubicin—pancreatic cancer	0.000947	0.00144	CcSEcCtD
Solifenacin—Asthenia—Irinotecan—pancreatic cancer	0.000945	0.00144	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000943	0.00144	CcSEcCtD
Solifenacin—Urinary tract infection—Epirubicin—pancreatic cancer	0.000936	0.00143	CcSEcCtD
Solifenacin—Dysuria—Doxorubicin—pancreatic cancer	0.000935	0.00143	CcSEcCtD
Solifenacin—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00093	0.00142	CcSEcCtD
Solifenacin—Dry mouth—Docetaxel—pancreatic cancer	0.000929	0.00142	CcSEcCtD
Solifenacin—Asthenia—Gemcitabine—pancreatic cancer	0.000921	0.0014	CcSEcCtD
Solifenacin—Confusional state—Docetaxel—pancreatic cancer	0.000918	0.0014	CcSEcCtD
Solifenacin—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000911	0.00139	CcSEcCtD
Solifenacin—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000911	0.00139	CcSEcCtD
Solifenacin—Pruritus—Gemcitabine—pancreatic cancer	0.000908	0.00138	CcSEcCtD
Solifenacin—Infection—Docetaxel—pancreatic cancer	0.000905	0.00138	CcSEcCtD
Solifenacin—Nervous system disorder—Docetaxel—pancreatic cancer	0.000893	0.00136	CcSEcCtD
Solifenacin—Pruritus—Fluorouracil—pancreatic cancer	0.000893	0.00136	CcSEcCtD
Solifenacin—Infestation NOS—Doxorubicin—pancreatic cancer	0.000891	0.00136	CcSEcCtD
Solifenacin—Infestation—Doxorubicin—pancreatic cancer	0.000891	0.00136	CcSEcCtD
Solifenacin—Tachycardia—Docetaxel—pancreatic cancer	0.000889	0.00136	CcSEcCtD
Solifenacin—Skin disorder—Docetaxel—pancreatic cancer	0.000885	0.00135	CcSEcCtD
Solifenacin—Renal failure—Doxorubicin—pancreatic cancer	0.000876	0.00134	CcSEcCtD
Solifenacin—Dizziness—Irinotecan—pancreatic cancer	0.000871	0.00133	CcSEcCtD
Solifenacin—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000866	0.00132	CcSEcCtD
Solifenacin—Pharyngitis—Epirubicin—pancreatic cancer	0.000858	0.00131	CcSEcCtD
Solifenacin—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000854	0.0013	CcSEcCtD
Solifenacin—Oedema peripheral—Epirubicin—pancreatic cancer	0.000852	0.0013	CcSEcCtD
Solifenacin—Connective tissue disorder—Epirubicin—pancreatic cancer	0.00085	0.0013	CcSEcCtD
Solifenacin—Urethral disorder—Epirubicin—pancreatic cancer	0.000848	0.00129	CcSEcCtD
Solifenacin—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000843	0.00129	CcSEcCtD
Solifenacin—Vomiting—Irinotecan—pancreatic cancer	0.000838	0.00128	CcSEcCtD
Solifenacin—Dizziness—Fluorouracil—pancreatic cancer	0.000834	0.00127	CcSEcCtD
Solifenacin—Rash—Irinotecan—pancreatic cancer	0.000831	0.00127	CcSEcCtD
Solifenacin—Dermatitis—Irinotecan—pancreatic cancer	0.00083	0.00127	CcSEcCtD
Solifenacin—Headache—Irinotecan—pancreatic cancer	0.000825	0.00126	CcSEcCtD
Solifenacin—Erythema multiforme—Epirubicin—pancreatic cancer	0.000817	0.00125	CcSEcCtD
Solifenacin—Vomiting—Gemcitabine—pancreatic cancer	0.000816	0.00124	CcSEcCtD
Solifenacin—Somnolence—Docetaxel—pancreatic cancer	0.00081	0.00124	CcSEcCtD
Solifenacin—Rash—Gemcitabine—pancreatic cancer	0.000809	0.00123	CcSEcCtD
Solifenacin—Dermatitis—Gemcitabine—pancreatic cancer	0.000808	0.00123	CcSEcCtD
Solifenacin—Eye disorder—Epirubicin—pancreatic cancer	0.000808	0.00123	CcSEcCtD
Solifenacin—Headache—Gemcitabine—pancreatic cancer	0.000804	0.00123	CcSEcCtD
Solifenacin—Cardiac disorder—Epirubicin—pancreatic cancer	0.000802	0.00122	CcSEcCtD
Solifenacin—Vomiting—Fluorouracil—pancreatic cancer	0.000802	0.00122	CcSEcCtD
Solifenacin—Dyspepsia—Docetaxel—pancreatic cancer	0.000802	0.00122	CcSEcCtD
Solifenacin—Rash—Fluorouracil—pancreatic cancer	0.000796	0.00121	CcSEcCtD
Solifenacin—Dermatitis—Fluorouracil—pancreatic cancer	0.000795	0.00121	CcSEcCtD
Solifenacin—Pharyngitis—Doxorubicin—pancreatic cancer	0.000794	0.00121	CcSEcCtD
Solifenacin—Decreased appetite—Docetaxel—pancreatic cancer	0.000792	0.00121	CcSEcCtD
Solifenacin—Headache—Fluorouracil—pancreatic cancer	0.00079	0.00121	CcSEcCtD
Solifenacin—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.00079	0.00121	CcSEcCtD
Solifenacin—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000788	0.0012	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000786	0.0012	CcSEcCtD
Solifenacin—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000786	0.0012	CcSEcCtD
Solifenacin—Fatigue—Docetaxel—pancreatic cancer	0.000785	0.0012	CcSEcCtD
Solifenacin—Angiopathy—Epirubicin—pancreatic cancer	0.000784	0.0012	CcSEcCtD
Solifenacin—Urethral disorder—Doxorubicin—pancreatic cancer	0.000784	0.0012	CcSEcCtD
Solifenacin—Nausea—Irinotecan—pancreatic cancer	0.000783	0.00119	CcSEcCtD
Solifenacin—Immune system disorder—Epirubicin—pancreatic cancer	0.000781	0.00119	CcSEcCtD
Solifenacin—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000779	0.00119	CcSEcCtD
Solifenacin—Constipation—Docetaxel—pancreatic cancer	0.000779	0.00119	CcSEcCtD
Solifenacin—Nausea—Gemcitabine—pancreatic cancer	0.000762	0.00116	CcSEcCtD
Solifenacin—Mental disorder—Epirubicin—pancreatic cancer	0.000757	0.00116	CcSEcCtD
Solifenacin—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000756	0.00115	CcSEcCtD
Solifenacin—Malnutrition—Epirubicin—pancreatic cancer	0.000753	0.00115	CcSEcCtD
Solifenacin—Feeling abnormal—Docetaxel—pancreatic cancer	0.00075	0.00114	CcSEcCtD
Solifenacin—Nausea—Fluorouracil—pancreatic cancer	0.000749	0.00114	CcSEcCtD
Solifenacin—Eye disorder—Doxorubicin—pancreatic cancer	0.000748	0.00114	CcSEcCtD
Solifenacin—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000745	0.00114	CcSEcCtD
Solifenacin—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000742	0.00113	CcSEcCtD
Solifenacin—Dysgeusia—Epirubicin—pancreatic cancer	0.000737	0.00112	CcSEcCtD
Solifenacin—Angiopathy—Doxorubicin—pancreatic cancer	0.000726	0.00111	CcSEcCtD
Solifenacin—Immune system disorder—Doxorubicin—pancreatic cancer	0.000723	0.0011	CcSEcCtD
Solifenacin—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000721	0.0011	CcSEcCtD
Solifenacin—Abdominal pain—Docetaxel—pancreatic cancer	0.00072	0.0011	CcSEcCtD
Solifenacin—Vision blurred—Epirubicin—pancreatic cancer	0.000709	0.00108	CcSEcCtD
Solifenacin—Mental disorder—Doxorubicin—pancreatic cancer	0.000701	0.00107	CcSEcCtD
Solifenacin—Malnutrition—Doxorubicin—pancreatic cancer	0.000696	0.00106	CcSEcCtD
Solifenacin—Dysgeusia—Doxorubicin—pancreatic cancer	0.000682	0.00104	CcSEcCtD
Solifenacin—Hypersensitivity—Docetaxel—pancreatic cancer	0.000671	0.00102	CcSEcCtD
Solifenacin—Palpitations—Epirubicin—pancreatic cancer	0.000665	0.00101	CcSEcCtD
Solifenacin—Cough—Epirubicin—pancreatic cancer	0.000657	0.001	CcSEcCtD
Solifenacin—Vision blurred—Doxorubicin—pancreatic cancer	0.000656	0.001	CcSEcCtD
Solifenacin—Asthenia—Docetaxel—pancreatic cancer	0.000653	0.000997	CcSEcCtD
Solifenacin—Hypertension—Epirubicin—pancreatic cancer	0.00065	0.000991	CcSEcCtD
Solifenacin—Pruritus—Docetaxel—pancreatic cancer	0.000644	0.000983	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000636	0.000971	CcSEcCtD
Solifenacin—Dry mouth—Epirubicin—pancreatic cancer	0.000627	0.000956	CcSEcCtD
Solifenacin—Confusional state—Epirubicin—pancreatic cancer	0.000619	0.000945	CcSEcCtD
Solifenacin—Palpitations—Doxorubicin—pancreatic cancer	0.000615	0.000939	CcSEcCtD
Solifenacin—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000614	0.000937	CcSEcCtD
Solifenacin—Infection—Epirubicin—pancreatic cancer	0.00061	0.000931	CcSEcCtD
Solifenacin—Cough—Doxorubicin—pancreatic cancer	0.000608	0.000927	CcSEcCtD
Solifenacin—Nervous system disorder—Epirubicin—pancreatic cancer	0.000602	0.000919	CcSEcCtD
Solifenacin—Dizziness—Docetaxel—pancreatic cancer	0.000602	0.000919	CcSEcCtD
Solifenacin—Hypertension—Doxorubicin—pancreatic cancer	0.000601	0.000917	CcSEcCtD
Solifenacin—Tachycardia—Epirubicin—pancreatic cancer	0.0006	0.000914	CcSEcCtD
Solifenacin—Skin disorder—Epirubicin—pancreatic cancer	0.000597	0.00091	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000589	0.000898	CcSEcCtD
Solifenacin—Dry mouth—Doxorubicin—pancreatic cancer	0.00058	0.000885	CcSEcCtD
Solifenacin—Vomiting—Docetaxel—pancreatic cancer	0.000579	0.000883	CcSEcCtD
Solifenacin—Rash—Docetaxel—pancreatic cancer	0.000574	0.000876	CcSEcCtD
Solifenacin—Dermatitis—Docetaxel—pancreatic cancer	0.000574	0.000875	CcSEcCtD
Solifenacin—Confusional state—Doxorubicin—pancreatic cancer	0.000573	0.000874	CcSEcCtD
Solifenacin—Headache—Docetaxel—pancreatic cancer	0.000571	0.00087	CcSEcCtD
Solifenacin—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000568	0.000867	CcSEcCtD
Solifenacin—Infection—Doxorubicin—pancreatic cancer	0.000565	0.000861	CcSEcCtD
Solifenacin—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000557	0.00085	CcSEcCtD
Solifenacin—Tachycardia—Doxorubicin—pancreatic cancer	0.000555	0.000846	CcSEcCtD
Solifenacin—Skin disorder—Doxorubicin—pancreatic cancer	0.000552	0.000842	CcSEcCtD
Solifenacin—Somnolence—Epirubicin—pancreatic cancer	0.000546	0.000833	CcSEcCtD
Solifenacin—Nausea—Docetaxel—pancreatic cancer	0.000541	0.000825	CcSEcCtD
Solifenacin—Dyspepsia—Epirubicin—pancreatic cancer	0.000541	0.000825	CcSEcCtD
Solifenacin—Decreased appetite—Epirubicin—pancreatic cancer	0.000534	0.000815	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.00053	0.000809	CcSEcCtD
Solifenacin—Fatigue—Epirubicin—pancreatic cancer	0.00053	0.000808	CcSEcCtD
Solifenacin—Constipation—Epirubicin—pancreatic cancer	0.000525	0.000801	CcSEcCtD
Solifenacin—Feeling abnormal—Epirubicin—pancreatic cancer	0.000506	0.000772	CcSEcCtD
Solifenacin—Somnolence—Doxorubicin—pancreatic cancer	0.000505	0.000771	CcSEcCtD
Solifenacin—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000502	0.000766	CcSEcCtD
Solifenacin—Dyspepsia—Doxorubicin—pancreatic cancer	0.0005	0.000763	CcSEcCtD
Solifenacin—Decreased appetite—Doxorubicin—pancreatic cancer	0.000494	0.000754	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000491	0.000749	CcSEcCtD
Solifenacin—Fatigue—Doxorubicin—pancreatic cancer	0.00049	0.000747	CcSEcCtD
Solifenacin—Urticaria—Epirubicin—pancreatic cancer	0.000488	0.000744	CcSEcCtD
Solifenacin—Constipation—Doxorubicin—pancreatic cancer	0.000486	0.000741	CcSEcCtD
Solifenacin—Abdominal pain—Epirubicin—pancreatic cancer	0.000486	0.000741	CcSEcCtD
Solifenacin—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000468	0.000714	CcSEcCtD
Solifenacin—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000465	0.000709	CcSEcCtD
Solifenacin—Hypersensitivity—Epirubicin—pancreatic cancer	0.000453	0.00069	CcSEcCtD
Solifenacin—Urticaria—Doxorubicin—pancreatic cancer	0.000452	0.000689	CcSEcCtD
Solifenacin—Abdominal pain—Doxorubicin—pancreatic cancer	0.000449	0.000685	CcSEcCtD
Solifenacin—Asthenia—Epirubicin—pancreatic cancer	0.000441	0.000672	CcSEcCtD
Solifenacin—Pruritus—Epirubicin—pancreatic cancer	0.000435	0.000663	CcSEcCtD
Solifenacin—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000419	0.000639	CcSEcCtD
Solifenacin—Asthenia—Doxorubicin—pancreatic cancer	0.000408	0.000622	CcSEcCtD
Solifenacin—Dizziness—Epirubicin—pancreatic cancer	0.000406	0.00062	CcSEcCtD
Solifenacin—Pruritus—Doxorubicin—pancreatic cancer	0.000402	0.000613	CcSEcCtD
Solifenacin—Vomiting—Epirubicin—pancreatic cancer	0.000391	0.000596	CcSEcCtD
Solifenacin—Rash—Epirubicin—pancreatic cancer	0.000387	0.000591	CcSEcCtD
Solifenacin—Dermatitis—Epirubicin—pancreatic cancer	0.000387	0.00059	CcSEcCtD
Solifenacin—Headache—Epirubicin—pancreatic cancer	0.000385	0.000587	CcSEcCtD
Solifenacin—Dizziness—Doxorubicin—pancreatic cancer	0.000376	0.000573	CcSEcCtD
Solifenacin—Nausea—Epirubicin—pancreatic cancer	0.000365	0.000557	CcSEcCtD
Solifenacin—Vomiting—Doxorubicin—pancreatic cancer	0.000361	0.000551	CcSEcCtD
Solifenacin—Rash—Doxorubicin—pancreatic cancer	0.000358	0.000547	CcSEcCtD
Solifenacin—Dermatitis—Doxorubicin—pancreatic cancer	0.000358	0.000546	CcSEcCtD
Solifenacin—Headache—Doxorubicin—pancreatic cancer	0.000356	0.000543	CcSEcCtD
Solifenacin—Nausea—Doxorubicin—pancreatic cancer	0.000338	0.000515	CcSEcCtD
Solifenacin—CHRM3—Signaling Pathways—CNR1—pancreatic cancer	8.11e-05	0.000235	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CNR1—pancreatic cancer	8.03e-05	0.000233	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CG—pancreatic cancer	7.89e-05	0.000229	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CG—pancreatic cancer	7.87e-05	0.000228	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TERT—pancreatic cancer	7.86e-05	0.000228	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—GCG—pancreatic cancer	7.86e-05	0.000228	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HIF1A—pancreatic cancer	7.85e-05	0.000228	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TSC2—pancreatic cancer	7.83e-05	0.000227	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—GCG—pancreatic cancer	7.83e-05	0.000227	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CG—pancreatic cancer	7.79e-05	0.000226	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—GCG—pancreatic cancer	7.75e-05	0.000225	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—APOE—pancreatic cancer	7.66e-05	0.000222	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PIK3CD—pancreatic cancer	7.64e-05	0.000222	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PIK3CD—pancreatic cancer	7.62e-05	0.000221	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—TYMS—pancreatic cancer	7.57e-05	0.00022	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PIK3CD—pancreatic cancer	7.54e-05	0.000219	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HIF1A—pancreatic cancer	7.52e-05	0.000218	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—KDR—pancreatic cancer	7.51e-05	0.000218	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TSC2—pancreatic cancer	7.5e-05	0.000218	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ARG2—pancreatic cancer	7.5e-05	0.000218	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AGTR1—pancreatic cancer	7.49e-05	0.000218	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AGTR1—pancreatic cancer	7.47e-05	0.000217	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AGTR1—pancreatic cancer	7.4e-05	0.000215	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—STK11—pancreatic cancer	7.39e-05	0.000214	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—STK11—pancreatic cancer	7.36e-05	0.000214	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—APOE—pancreatic cancer	7.34e-05	0.000213	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—STK11—pancreatic cancer	7.29e-05	0.000212	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—KDR—pancreatic cancer	7.19e-05	0.000209	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NFKBIA—pancreatic cancer	7.14e-05	0.000207	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NOTCH1—pancreatic cancer	7.07e-05	0.000205	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CD—pancreatic cancer	6.94e-05	0.000201	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CD—pancreatic cancer	6.92e-05	0.000201	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CG—pancreatic cancer	6.92e-05	0.000201	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—NRAS—pancreatic cancer	6.92e-05	0.000201	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CD—pancreatic cancer	6.85e-05	0.000199	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NFKBIA—pancreatic cancer	6.84e-05	0.000199	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EGF—pancreatic cancer	6.84e-05	0.000198	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NOTCH1—pancreatic cancer	6.77e-05	0.000197	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.66e-05	0.000193	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.64e-05	0.000193	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CG—pancreatic cancer	6.62e-05	0.000192	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—NRAS—pancreatic cancer	6.62e-05	0.000192	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.57e-05	0.000191	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TYMP—pancreatic cancer	6.55e-05	0.00019	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EGF—pancreatic cancer	6.55e-05	0.00019	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SMAD4—pancreatic cancer	6.47e-05	0.000188	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SMAD4—pancreatic cancer	6.45e-05	0.000187	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	6.4e-05	0.000186	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SMAD4—pancreatic cancer	6.39e-05	0.000185	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CXCL8—pancreatic cancer	6.38e-05	0.000185	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CXCL8—pancreatic cancer	6.32e-05	0.000183	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HES1—pancreatic cancer	6.32e-05	0.000183	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—EGFR—pancreatic cancer	6.3e-05	0.000183	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HES1—pancreatic cancer	6.3e-05	0.000183	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HES1—pancreatic cancer	6.23e-05	0.000181	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—APOE—pancreatic cancer	6.16e-05	0.000179	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CD—pancreatic cancer	6.08e-05	0.000177	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	6.05e-05	0.000176	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—EGFR—pancreatic cancer	6.03e-05	0.000175	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CB—pancreatic cancer	6.03e-05	0.000175	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.02e-05	0.000175	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CB—pancreatic cancer	5.97e-05	0.000173	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—KRAS—pancreatic cancer	5.95e-05	0.000173	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CD—pancreatic cancer	5.82e-05	0.000169	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CXCL8—pancreatic cancer	5.81e-05	0.000169	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCL8—pancreatic cancer	5.79e-05	0.000168	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.77e-05	0.000167	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCL8—pancreatic cancer	5.74e-05	0.000167	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—KRAS—pancreatic cancer	5.7e-05	0.000165	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CG—pancreatic cancer	5.56e-05	0.000161	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TERT—pancreatic cancer	5.53e-05	0.000161	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TERT—pancreatic cancer	5.52e-05	0.00016	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—PIK3CA—pancreatic cancer	5.47e-05	0.000159	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TERT—pancreatic cancer	5.46e-05	0.000159	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PPARG—pancreatic cancer	5.37e-05	0.000156	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CB—pancreatic cancer	5.3e-05	0.000154	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	5.29e-05	0.000154	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GLP1R—pancreatic cancer	5.28e-05	0.000153	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	5.28e-05	0.000153	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HIF1A—pancreatic cancer	5.28e-05	0.000153	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TSC2—pancreatic cancer	5.26e-05	0.000153	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—PIK3CA—pancreatic cancer	5.24e-05	0.000152	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HIF1A—pancreatic cancer	5.22e-05	0.000152	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TSC2—pancreatic cancer	5.21e-05	0.000151	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—DPYD—pancreatic cancer	5.2e-05	0.000151	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APOE—pancreatic cancer	5.17e-05	0.00015	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APOE—pancreatic cancer	5.15e-05	0.00015	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APOE—pancreatic cancer	5.1e-05	0.000148	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCL8—pancreatic cancer	5.09e-05	0.000148	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CB—pancreatic cancer	5.07e-05	0.000147	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KDR—pancreatic cancer	5.06e-05	0.000147	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—HRAS—pancreatic cancer	5.06e-05	0.000147	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KDR—pancreatic cancer	5.05e-05	0.000146	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KDR—pancreatic cancer	5e-05	0.000145	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	4.93e-05	0.000143	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—AKT1—pancreatic cancer	4.92e-05	0.000143	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CD—pancreatic cancer	4.89e-05	0.000142	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCL8—pancreatic cancer	4.88e-05	0.000142	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CASP3—pancreatic cancer	4.87e-05	0.000142	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—HRAS—pancreatic cancer	4.84e-05	0.000141	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	4.81e-05	0.00014	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NFKBIA—pancreatic cancer	4.8e-05	0.000139	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	4.77e-05	0.000138	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOTCH1—pancreatic cancer	4.75e-05	0.000138	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NFKBIA—pancreatic cancer	4.75e-05	0.000138	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCND1—pancreatic cancer	4.74e-05	0.000138	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AKT1—pancreatic cancer	4.71e-05	0.000137	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOTCH1—pancreatic cancer	4.71e-05	0.000137	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CTNNB1—pancreatic cancer	4.7e-05	0.000136	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CASP3—pancreatic cancer	4.67e-05	0.000136	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	4.66e-05	0.000135	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	4.66e-05	0.000135	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CG—pancreatic cancer	4.65e-05	0.000135	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—NRAS—pancreatic cancer	4.65e-05	0.000135	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGF—pancreatic cancer	4.61e-05	0.000134	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MMP9—pancreatic cancer	4.61e-05	0.000134	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CG—pancreatic cancer	4.6e-05	0.000134	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—NRAS—pancreatic cancer	4.6e-05	0.000134	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGF—pancreatic cancer	4.59e-05	0.000133	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PTEN—pancreatic cancer	4.58e-05	0.000133	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGF—pancreatic cancer	4.55e-05	0.000132	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCND1—pancreatic cancer	4.54e-05	0.000132	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CTNNB1—pancreatic cancer	4.5e-05	0.000131	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AKT1—pancreatic cancer	4.47e-05	0.00013	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MMP9—pancreatic cancer	4.41e-05	0.000128	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PTEN—pancreatic cancer	4.38e-05	0.000127	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AKT1—pancreatic cancer	4.28e-05	0.000124	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CB—pancreatic cancer	4.26e-05	0.000124	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	4.25e-05	0.000123	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SRC—pancreatic cancer	4.25e-05	0.000123	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—EGFR—pancreatic cancer	4.23e-05	0.000123	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTGS2—pancreatic cancer	4.22e-05	0.000123	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—EGFR—pancreatic cancer	4.19e-05	0.000122	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—VEGFA—pancreatic cancer	4.14e-05	0.00012	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	4.1e-05	0.000119	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—STAT3—pancreatic cancer	4.1e-05	0.000119	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CD—pancreatic cancer	4.09e-05	0.000119	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NRAS—pancreatic cancer	4.09e-05	0.000119	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SRC—pancreatic cancer	4.07e-05	0.000118	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.06e-05	0.000118	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.05e-05	0.000118	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CD—pancreatic cancer	4.05e-05	0.000117	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	4.01e-05	0.000117	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.01e-05	0.000116	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—KRAS—pancreatic cancer	4e-05	0.000116	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—KRAS—pancreatic cancer	3.96e-05	0.000115	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—VEGFA—pancreatic cancer	3.96e-05	0.000115	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—STAT3—pancreatic cancer	3.92e-05	0.000114	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NRAS—pancreatic cancer	3.91e-05	0.000114	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CD44—pancreatic cancer	3.82e-05	0.000111	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MYC—pancreatic cancer	3.81e-05	0.00011	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFB1—pancreatic cancer	3.8e-05	0.00011	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EGFR—pancreatic cancer	3.72e-05	0.000108	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	3.69e-05	0.000107	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTEN—pancreatic cancer	3.68e-05	0.000107	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CA—pancreatic cancer	3.68e-05	0.000107	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GCG—pancreatic cancer	3.66e-05	0.000106	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MYC—pancreatic cancer	3.64e-05	0.000106	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CA—pancreatic cancer	3.64e-05	0.000106	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFB1—pancreatic cancer	3.64e-05	0.000106	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	3.57e-05	0.000104	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EGFR—pancreatic cancer	3.56e-05	0.000103	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CB—pancreatic cancer	3.56e-05	0.000103	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CB—pancreatic cancer	3.53e-05	0.000102	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—KRAS—pancreatic cancer	3.52e-05	0.000102	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—STK11—pancreatic cancer	3.44e-05	9.99e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	3.43e-05	9.97e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL8—pancreatic cancer	3.42e-05	9.94e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	3.41e-05	9.9e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—HRAS—pancreatic cancer	3.4e-05	9.87e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL8—pancreatic cancer	3.39e-05	9.84e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—HRAS—pancreatic cancer	3.37e-05	9.78e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—KRAS—pancreatic cancer	3.37e-05	9.78e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	3.32e-05	9.63e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AKT1—pancreatic cancer	3.31e-05	9.6e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	3.29e-05	9.54e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CASP3—pancreatic cancer	3.28e-05	9.51e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	3.27e-05	9.51e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	3.24e-05	9.42e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CA—pancreatic cancer	3.23e-05	9.38e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	3.2e-05	9.29e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCND1—pancreatic cancer	3.19e-05	9.26e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	3.17e-05	9.2e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	3.16e-05	9.17e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	3.16e-05	9.17e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	3.13e-05	9.08e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TP53—pancreatic cancer	3.12e-05	9.07e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	3.11e-05	9.02e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	3.1e-05	8.99e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CA—pancreatic cancer	3.09e-05	8.98e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	3.09e-05	8.96e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	3.08e-05	8.94e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	3.07e-05	8.9e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	3.05e-05	8.85e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	3.01e-05	8.74e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	3e-05	8.72e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TP53—pancreatic cancer	2.99e-05	8.69e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HRAS—pancreatic cancer	2.99e-05	8.68e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	2.97e-05	8.63e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.96e-05	8.6e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SRC—pancreatic cancer	2.86e-05	8.31e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HRAS—pancreatic cancer	2.86e-05	8.31e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SRC—pancreatic cancer	2.85e-05	8.29e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SRC—pancreatic cancer	2.83e-05	8.21e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	2.79e-05	8.1e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	2.78e-05	8.07e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	2.76e-05	8.02e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	2.75e-05	8e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	2.75e-05	7.99e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	2.75e-05	7.99e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	2.75e-05	7.97e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	2.73e-05	7.91e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	2.72e-05	7.89e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AKT1—pancreatic cancer	2.64e-05	7.66e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CA—pancreatic cancer	2.6e-05	7.54e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MYC—pancreatic cancer	2.57e-05	7.45e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	2.56e-05	7.43e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MYC—pancreatic cancer	2.56e-05	7.43e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	2.55e-05	7.41e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MYC—pancreatic cancer	2.53e-05	7.35e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKT1—pancreatic cancer	2.53e-05	7.34e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	2.53e-05	7.34e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	2.51e-05	7.29e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	2.5e-05	7.26e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	2.48e-05	7.19e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOE—pancreatic cancer	2.41e-05	6.99e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	2.37e-05	6.88e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	2.36e-05	6.86e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	2.34e-05	6.79e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	2.18e-05	6.32e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.17e-05	6.31e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	2.17e-05	6.3e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	2.15e-05	6.24e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AKT1—pancreatic cancer	2.12e-05	6.16e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TP53—pancreatic cancer	2.11e-05	6.12e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TP53—pancreatic cancer	2.1e-05	6.1e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.1e-05	6.09e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TP53—pancreatic cancer	2.08e-05	6.04e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	2.02e-05	5.85e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	2.01e-05	5.83e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	1.99e-05	5.78e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.91e-05	5.55e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	1.78e-05	5.17e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	1.77e-05	5.15e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	1.76e-05	5.1e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.67e-05	4.83e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.65e-05	4.79e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.44e-05	4.18e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.02e-05	2.95e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AKT1—pancreatic cancer	8.29e-06	2.41e-05	CbGpPWpGaD
